journal article·2026-06-26Open access

Self‐Sustaining Lactate Depletion Nanoplatform Remodels Tumor Microenvironment and Augments Synergistic Photodynamic/Photothermal/Chemodynamic/Starvation Therapy for Eradication of Colon Cancer

Yu‐E. Wang, Shibo Zhao, Wenying Wu, Zhiwei Duan, Yuan Li, Xiangyu Zeng, Liang Hong, Yan Chen, Ling Tao, Kewu Zeng, Chaoda Xiao, Xiangchun Shen

Abstract

ABSTRACT Colon cancer remains a formidable therapeutic challenge due to its high malignancy and limited treatment options. To overcome this, we develop a multifunctional nanoplatform (HILA) using hollow mesoporous manganese dioxide (HMnO 2 ) to co‐load lactate oxidase (LOX) and the photosensitizer indocyanine green (ICG), coated with hyaluronic acid (HA) for targeted delivery to CD44‐overexpressing tumor cells. Within the tumor microenvironment (TME), LOX converts lactate to more acidic pyruvate and H 2 O 2 , which subsequently react with HMnO 2 to produce O 2 , establishing a self‐sustaining HMnO 2 ‐LOX catalytic cycle that continuously depletes lactate (inducing tumor starvation) while alleviating hypoxia. The acidic pyruvate accelerates HMnO 2 degradation, releasing ICG and Mn 2+ ions. Under near‐infrared irradiation, the generated O 2 facilitates photodynamic/photothermal therapy (PDT/PTT) of ICG, while Mn 2+ catalyzes H 2 O 2 to generate hydroxyl radicals (•OH) for enhanced chemodynamic therapy (CDT). Crucially, the coordinated TME remodeling, (featuring lactate exhaustion, pH reduction, and O 2 /H 2 O 2 accumulation) creates a positive feedback loop that fuels PDT/PTT/CDT/starvation therapy. This self‐reinforcing cycle integrates PDT/PTT/CDT/starvation therapy, demonstrating potent tumor suppression in vivo and offering a paradigm for metabolic modulation‐synergized oncotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences Guizhou International Science & Technology Cooperation Base for Druggability Research of Natural Medicines The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province the Key Laboratory of Optimal Utilization of Natural Medicine Resources Guizhou Medical University Guizhou China

School of Biology and Engineering Guizhou Medical University Guizhou China

Key Laboratory of Novel Anti‐Cancer Drug Targets Discovery and Application School of Pharmaceutical Sciences Guizhou Medical University Guizhou China

National Key Laboratory of Natural and Biomimetic Drugs Peking University Beijing China

References (49)

Show source-provided references
1. 10.1007/s10120‐021‐01265‐710.1007/s10120‐021‐01265‐7 ↗
2. 10.1002/med.2180910.1002/med.21809 ↗
3. 10.1021/acsami.9b0423610.1021/acsami.9b04236 ↗
4. 10.1002/adma.20130092910.1002/adma.201300929 ↗
5. 10.1126/science.116080910.1126/science.1160809 ↗
6. 10.1186/s12951‐022‐01762‐610.1186/s12951‐022‐01762‐6 ↗
7. 10.1021/acsami.2c0725410.1021/acsami.2c07254 ↗
8. 10.1016/j.cell.2024.04.00210.1016/j.cell.2024.04.002 ↗
9. 10.1016/j.cell.2023.11.02210.1016/j.cell.2023.11.022 ↗
10. 10.3389/fimmu.2019.0227810.3389/fimmu.2019.02278 ↗
11. 10.1038/nnano.2016.5410.1038/nnano.2016.54 ↗
12. 10.1039/d0tb02360d10.1039/d0tb02360d ↗
13. 10.1038/s41467‐017‐01050‐010.1038/s41467‐017‐01050‐0 ↗
14. 10.1021/acsami.2c1896010.1021/acsami.2c18960 ↗
15. 10.1021/acsabm.0c0004210.1021/acsabm.0c00042 ↗
16. 10.1039/d1ra03469c10.1039/d1ra03469c ↗
17. 10.1002/smll.20210651110.1002/smll.202106511 ↗
18. 10.1021/acsami.1c0431010.1021/acsami.1c04310 ↗
19. 10.7150/thno.6730010.7150/thno.67300 ↗
20. 10.1016/j.jconrel.2020.06.03210.1016/j.jconrel.2020.06.032 ↗
21. 10.1002/smll.20220607810.1002/smll.202206078 ↗
22. 10.4174/astr.2023.105.5.25210.4174/astr.2023.105.5.252 ↗
23. 10.1038/s41467‐022‐30306‐710.1038/s41467‐022‐30306‐7 ↗
24. 10.1016/j.biomaterials.2020.12034610.1016/j.biomaterials.2020.120346 ↗
25. 10.1117/1.Jbo.17.4.04600310.1117/1.Jbo.17.4.046003 ↗
26. 10.3390/cancers1404103610.3390/cancers14041036 ↗
27. 10.7150/thno.2287210.7150/thno.22872 ↗
28. 10.1039/d3bm00834g10.1039/d3bm00834g ↗
29. 10.1039/d2nr90218d10.1039/d2nr90218d ↗
30. 10.1039/d3mh00717k10.1039/d3mh00717k ↗
31. 10.1021/acsami.4c1628710.1021/acsami.4c16287 ↗
32. 10.1016/j.jcis.2022.02.13210.1016/j.jcis.2022.02.132 ↗
33. 10.3390/pharmaceutics1502032710.3390/pharmaceutics15020327 ↗
34. 10.1016/j.pdpdt.2023.10364810.1016/j.pdpdt.2023.103648 ↗
35. 10.1021/acsami.8b0027610.1021/acsami.8b00276 ↗
36. 10.1016/j.apmt.2019.02.00210.1016/j.apmt.2019.02.002 ↗
37. 10.1016/j.isci.2025.11322010.1016/j.isci.2025.113220 ↗
38. 10.3390/ijms2409833910.3390/ijms24098339 ↗
39. 10.1039/d5ma00278h10.1039/d5ma00278h ↗
40. 10.1021/cr500419810.1021/cr5004198 ↗
41. 10.1016/j.jphotochem.2019.02.02810.1016/j.jphotochem.2019.02.028 ↗
42. 10.1016/j.colsurfb.2023.11339510.1016/j.colsurfb.2023.113395 ↗
43. 10.1038/s41392‐024‐02082‐x10.1038/s41392‐024‐02082‐x ↗
44. 10.1021/acsami.8b1020710.1021/acsami.8b10207 ↗
45. 10.1016/j.biomaterials.2020.12032910.1016/j.biomaterials.2020.120329 ↗
46. 10.2174/010929867325102523091910581810.2174/0109298673251025230919105818 ↗
47. 10.1021/acsami.9b2332510.1021/acsami.9b23325 ↗
48. 10.1016/j.actbio.2022.05.03010.1016/j.actbio.2022.05.030 ↗
49. 10.1016/j.biomaterials.2022.12168810.1016/j.biomaterials.2022.121688 ↗